Barclays analyst Etzer Darout raised the firm’s price target on C4 Therapeutics (CCCC) to $10 from $8 and keeps an Overweight rating on the shares after the company presented over the weekend updated Phase 1 dose escalation data for cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. The data support a clinical benefit profile that is differentiated in multiple myeloma, the analyst tells investors in a research note. Barclays points out that across all doses, 34% of patients achieved a partial response.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics Reports Promising Phase 1 Trial Results
- C4 Therapeutics: Balancing Promise and Competition in the Multiple Myeloma Market
- C4 Therapeutics presents data from Phase 1 trial of cemsidomide
- C4 Therapeutics initiated with an Overweight at Barclays
- C4 Therapeutics: Promising Growth and Competitive Edge with TORPEDO Platform and Strategic Partnerships